


SUPPLEMENTARY FIG. S4. Likelihood of choosing a new HIV remission strategy over standard daily HIV medication under different scenarios (United States, 2018). Percentages on the *left* reflect the sum of “not at all likely” and “somewhat unlikely” to switch to the new HIV remission strategy and abandon current standard daily HIV medication strategy. Percentages on the *right* reflect “very likely” and “moderately likely” to switch to the new HIV remission strategy.



SUPPLEMENTARY FIG. S5. Acceptability of factors under new HIV remission strategy compared with experiences with standard HIV medications (United States, 2018). Percentages on the *left* reflect the sum of “unacceptable” and “very bothered” by the factor of the new HIV remission strategy compared with experience with standard HIV medications. Percentages on the *right* reflect the sum of “not bothered” and “somewhat bothered” by the factor of the new HIV remission strategy compared with experience with standard HIV medications.